Lutetium-177 (177 Lu), whose radio-decay characteristics have specific advantages for radiotherapy. The goal is to identify potential carrier molecules that target some of the major cancers for ...

The production of all n.c.a. Lu-177 depends on a complex and very limited global supply chain which up to now has predominantly been dependent on supply from Russia. Kinectrics is expanding our ...

Lutetium-177 is integral to this approach due to its favorable decay properties and compatibility with various targeting molecules. The success of targeted radiotherapy in clinical trials and real ...

Lutetium-177 vipivotide tetraxetan 1 is a widely approved breakthrough drug for metastatic prostate cancer. It is manufactured and distributed by Novartis (Basel, Switzerland) under the trade name ...

Today’s announcement follows Curium’s news earlier in 2024 of further securing its robust supply chain of Lu-177 with multiple irradiation partners which enables Curium to start delivering samples to ...

Lutetium-177 (Lu-177) Market is Segmented by Type (Non-carrier-added, Carrier-added), by Application (Nuclear Therapy, Others). BANGALORE, India, Feb. 18, 2025 /PRNewswire/ -- The Global Anzeige ...